• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Abivax SA

    11/14/25 4:22:54 PM ET
    $ABVX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABVX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Abivax SA

    (Name of Issuer)


    Ordinary Shares, par value Euro 0.01 per share

    (Title of Class of Securities)


    00370M103

    (CUSIP Number)


    09/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    00370M103


    1Names of Reporting Persons

    TCG Crossover GP I, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    6,456,596.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    6,456,596.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,456,596.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.3 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:   Consists of 6,456,596 ordinary shares (as defined in Item 2(d) below) in the form of American Depositary Shares ("ADSs") of the Issuer (as defined in Item 1(a) below) held of record by TCG Crossover I (as defined in Item 2(a) below). Each ADS represents one (1) ordinary share. TCG Crossover GP I (as defined in Item 2(a) below) is the general partner of TCG Crossover I and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP I and may be deemed to share voting, investment and dispositive power with respect to these securities. Based on 77,830,067 ordinary shares outstanding as of September 30, 2025, as provided to the Reporting Persons by the Issuer.


    SCHEDULE 13G

    CUSIP No.
    00370M103


    1Names of Reporting Persons

    TCG Crossover Fund I, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    6,456,596.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    6,456,596.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,456,596.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.3 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:   Consists of 6,456,596 ordinary shares in the form of ADSs of the Issuer held of record by TCG Crossover I. Each ADS represents one (1) ordinary share. TCG Crossover GP I is the general partner of TCG Crossover I and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP I and may be deemed to share voting, investment and dispositive power with respect to these securities. Based on 77,830,067 ordinary shares outstanding as of September 30, 2025, as provided to the Reporting Persons by the Issuer.


    SCHEDULE 13G

    CUSIP No.
    00370M103


    1Names of Reporting Persons

    TCG Crossover GP II, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    655,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    655,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    655,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.8 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:   Consists of 655,000 ordinary shares in the form of ADSs of the Issuer held of record by TCG Crossover II (as defined in Item 2(a) below). Each ADS represents one (1) ordinary share. TCG Crossover GP II (as defined in Item 2(a) below) is the general partner of TCG Crossover II and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP II and may be deemed to share voting, investment and dispositive power with respect to these securities. Based on 77,830,067 ordinary shares outstanding as of September 30, 2025, as provided to the Reporting Persons by the Issuer.


    SCHEDULE 13G

    CUSIP No.
    00370M103


    1Names of Reporting Persons

    TCG Crossover Fund II, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    655,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    655,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    655,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.8 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:   Consists of 655,000 ordinary shares in the form of ADSs of the Issuer held of record by TCG Crossover II. Each ADS represents one (1) ordinary share. TCG Crossover GP II is the general partner of TCG Crossover II and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP II and may be deemed to share voting, investment and dispositive power with respect to these securities. Based on 77,830,067 ordinary shares outstanding as of September 30, 2025, as provided to the Reporting Persons by the Issuer.


    SCHEDULE 13G

    CUSIP No.
    00370M103


    1Names of Reporting Persons

    Chen Yu
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    7,111,596.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    7,111,596.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,111,596.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.1 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:   Consists of (i) 6,456,596 ordinary shares in the form of ADSs of the Issuer held of record by TCG Crossover I and (ii) 655,000 ordinary shares in the form of ADSs of the Issuer held of record by TCG Crossover II. TCG Crossover GP I is the general partner of TCG Crossover I and may be deemed to have voting, investment, and dispositive power with respect to the securities held of record by TCG Crossover I. TCG Crossover GP II is the general partner of TCG Crossover II and may be deemed to have voting, investment, and dispositive power with respect to the securities held of record by TCG Crossover II. Chen Yu is the sole managing member of each of TCG Crossover GP I and TCG Crossover GP II and may be deemed to share voting, investment and dispositive power with respect to the securities held of record by TCG Crossover II and TCG Crossover II. Based on 77,830,067 ordinary shares outstanding as of September 30, 2025, as provided to the Reporting Persons by the Issuer.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Abivax SA
    (b)Address of issuer's principal executive offices:

    7-11 boulevard Haussman, Paris, France, 75009
    Item 2. 
    (a)Name of person filing:

    This Amendment No. 1 (Amendment No. 1) amends and supplements the Schedule 13G initially filed with the Commission on April 19, 2024 (the Original Schedule 13G) and is being filed by TCG Crossover Fund I, L.P. (TCG Crossover I), TCG Crossover GP I, LLC (TCG Crossover GP I), TCG Crossover Fund II, L.P. (TCG Crossover II) and TCG Crossover GP II, LLC (TCG Crossover GP II and together with TCG Crossover I, TCG Crossover GP I and TCG Crossover II, the Reporting Entities) and Chen Yu (the Reporting Individual). The Reporting Entities and the Reporting Individual are collectively referred to as the Reporting Persons. The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13G. The agreement among the Reporting Persons to file jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act is attached to this Statement as Exhibit 2. Other than those securities reported herein as being held directly by such Reporting Person, each Reporting Person disclaims beneficial ownership of all securities reported in this Amendment No. 1 except to the extent of such Reporting Person's pecuniary interest therein.
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of each Reporting Person is 245 Lytton Ave., Suite 350, Palo Alto, CA 94301.
    (c)Citizenship:

    TCG Crossover GP I and TCG Crossover GP II are each a limited liability company organized under the laws of the State of Delaware. TCG Crossover I and TCG Crossover II are each a limited partnership organized under the laws of the State of Delaware. The Reporting Individual is a citizen of the United States of America.
    (d)Title of class of securities:

    Ordinary Shares, par value Euro 0.01 per share
    (e)CUSIP No.:

    00370M103
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See Row 9 of the cover page for each Reporting Person and the corresponding footnotes. Each of the Reporting Persons disclaims beneficial ownership as to such securities, except to the extent of his or its pecuniary interest therein.
    (b)Percent of class:

    See Row 11 of the cover page for each Reporting Person and the corresponding footnotes. Each of the Reporting Persons disclaims beneficial ownership as to such securities, except to the extent of his or its pecuniary interest therein.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See Row 5 of the cover page for each Reporting Person and the corresponding footnotes. Each of the Reporting Persons disclaims beneficial ownership as to such securities, except to the extent of his or its pecuniary interest therein.

     (ii) Shared power to vote or to direct the vote:

    See Row 6 of the cover page for each Reporting Person and the corresponding footnotes. Each of the Reporting Persons disclaims beneficial ownership as to such securities, except to the extent of his or its pecuniary interest therein.

     (iii) Sole power to dispose or to direct the disposition of:

    See Row 7 of the cover page for each Reporting Person and the corresponding footnotes. Each of the Reporting Persons disclaims beneficial ownership as to such securities, except to the extent of his or its pecuniary interest therein.

     (iv) Shared power to dispose or to direct the disposition of:

    See Row 8 of the cover page for each Reporting Person and the corresponding footnotes. Each of the Reporting Persons disclaims beneficial ownership as to such securities, except to the extent of his or its pecuniary interest therein.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    Under certain circumstances set forth in the limited partnership agreements of TCG Crossover I and TCG Crossover II and the limited liability company agreements of TCG Crossover GP I and TCG Crossover GP II, the general and limited partners or members, as the case may be, of each of such entities may be deemed to have the right to receive dividends from, or the proceeds from, the sale of securities of the Issuer owned by each such entity of which they are a partner or member, as the case may be.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    TCG Crossover GP I, LLC
     
    Signature:/s/ Craig Skaling
    Name/Title:Craig Skaling, Authorized Signatory
    Date:11/14/2025
     
    TCG Crossover Fund I, L.P.
     
    Signature:/s/ Craig Skaling
    Name/Title:Craig Skaling, Authorized Signatory
    Date:11/14/2025
     
    TCG Crossover GP II, LLC
     
    Signature:/s/ Craig Skaling
    Name/Title:Craig Skaling, Authorized Signatory
    Date:11/14/2025
     
    TCG Crossover Fund II, L.P.
     
    Signature:/s/ Craig Skaling
    Name/Title:Craig Skaling, Authorized Signatory
    Date:11/14/2025
     
    Chen Yu
     
    Signature:/s/ Craig Skaling
    Name/Title:Craig Skaling, as Attorney-in-Fact for Chen Yu
    Date:11/14/2025
    Get the next $ABVX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABVX

    DatePrice TargetRatingAnalyst
    11/24/2025Buy
    Truist
    11/6/2025$176.00Outperform
    Wolfe Research
    10/13/2025$142.00Overweight
    Barclays
    7/23/2025$71.00Equal-Weight → Overweight
    Morgan Stanley
    3/20/2025$12.00Equal-Weight
    Morgan Stanley
    12/4/2024$33.00Mkt Outperform
    JMP Securities
    7/29/2024$48.00Buy
    Laidlaw
    5/20/2024$43.00Buy
    BTIG Research
    More analyst ratings

    $ABVX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Truist initiated coverage on Abivax SA

    Truist initiated coverage of Abivax SA with a rating of Buy

    11/24/25 8:30:31 AM ET
    $ABVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wolfe Research initiated coverage on Abivax SA with a new price target

    Wolfe Research initiated coverage of Abivax SA with a rating of Outperform and set a new price target of $176.00

    11/6/25 8:47:47 AM ET
    $ABVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Abivax SA with a new price target

    Barclays initiated coverage of Abivax SA with a rating of Overweight and set a new price target of $142.00

    10/13/25 8:51:16 AM ET
    $ABVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis

    Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis Improvements across all patient reported outcomes (PROs) were observed from baseline to Week 8 in all PRO instruments utilized in the ABTECT induction trials evaluating bowel urgency, sleep interruption, fatigue, quality of life, and work productivity for both 50mg and 25mg once-daily obefazimod.At week 8 in the ABTECT 1 & 2 trials, 37% of patients taking once daily 50mg obefazimod reported no bowel urgency (BU) compared to 18.1% of patients in the placebo group (18.

    11/3/25 4:05:00 PM ET
    $ABVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies

    Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies 50 mg dose of once-daily obefazimod achieved clinically meaningful improvements, across all endpoints, regardless of prior inadequate response to advanced therapies (AT-IR) 50mg dose demonstrated clinically meaningful improvements in clinical remission in participants with and without prior inadequate response to up to 4+ lines of advanced therapies including JAK inhibitors in the pooled ABTECT 1 & 2 Trials (w/AT-IR pbo adjusted D 10%, p=0.0009†; w/o AT-IR pbo adjusted D 22%, p<0.0001†)50mg obefazimod demonstrated clinically me

    10/6/25 4:00:00 AM ET
    $ABVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data

    Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data 50 mg once-daily dose of obefazimod led to a pooled 16.4% (p<0.0001) placebo-adjusted clinical remission rate at Week 8; met primary and all key secondary endpoints in both ABTECT 1 and ABTECT 2ABTECT trials enrolled refractory patient population with 47% of participants having prior inadequate response to advanced therapy, among whom 21% had prior inadequate response to JAK inhibitor therapyObefazimod treatment was well tolerated with no new safety signals identified for both the 25mg and 50mg doses Abivax to present a second late-breaking abstract on October 6. Management to host a conferen

    10/5/25 11:00:00 AM ET
    $ABVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Abivax SA

    SCHEDULE 13G/A - Abivax S.A. (0001956827) (Subject)

    11/14/25 5:29:17 PM ET
    $ABVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Abivax SA

    SCHEDULE 13G/A - Abivax S.A. (0001956827) (Subject)

    11/14/25 4:22:54 PM ET
    $ABVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Abivax SA

    SCHEDULE 13D/A - Abivax S.A. (0001956827) (Subject)

    10/30/25 4:08:59 PM ET
    $ABVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVX
    Leadership Updates

    Live Leadership Updates

    View All

    Abivax Announces Results of its June 6, 2025 Annual General Meeting

    Abivax Announces Results of its June 6, 2025 Annual General Meeting PARIS, France, June 11, 2025, 10:00 p.m. CEST – Abivax SA (PARIS:FR) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, held its annual general meeting of shareholders on June 6, 2025 (the "General Meeting"), which was chaired by Ms. Sylvie Grégoire Chairman of the Board of Directors of Abivax ("Board"). The shareholders have adopted all the resolutions proposed by the Board, and particularly the financial statements for the 2024 fina

    6/11/25 4:00:00 PM ET
    $ABVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors

    Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors Industry veteran brings deep immunology expertise ahead of key Phase 3 data readout in ulcerative colitis expected in Q3 2025 PARIS, France, April 22, 2025, 10:00 pm CEST – Abivax SA (PARIS:FR, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the appointment of Dominik Höchli, MD to the Board of Directors of Abivax, effective immediately. Dr. Höchli brings over two decades of leadership experience in

    4/22/25 4:00:00 PM ET
    $ABVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax

    Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax PARIS, France, November 13, 2024, 10:00 pm CET – Abivax SA (Euronext Paris and Nasdaq: ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the appointment of Mark Stenhouse as Board Observer and Advisor to Abivax. Mr. Stenhouse brings more than 30 years of experience in the biopharma industry. Most recently, he served as Chief Operating Officer of Prometheus Biosciences, a biotechn

    11/13/24 4:01:00 PM ET
    $ABVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVX
    Financials

    Live finance-specific insights

    View All

    Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies

    Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies 50 mg dose of once-daily obefazimod achieved clinically meaningful improvements, across all endpoints, regardless of prior inadequate response to advanced therapies (AT-IR) 50mg dose demonstrated clinically meaningful improvements in clinical remission in participants with and without prior inadequate response to up to 4+ lines of advanced therapies including JAK inhibitors in the pooled ABTECT 1 & 2 Trials (w/AT-IR pbo adjusted D 10%, p=0.0009†; w/o AT-IR pbo adjusted D 22%, p<0.0001†)50mg obefazimod demonstrated clinically me

    10/6/25 4:00:00 AM ET
    $ABVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data

    Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data 50 mg once-daily dose of obefazimod led to a pooled 16.4% (p<0.0001) placebo-adjusted clinical remission rate at Week 8; met primary and all key secondary endpoints in both ABTECT 1 and ABTECT 2ABTECT trials enrolled refractory patient population with 47% of participants having prior inadequate response to advanced therapy, among whom 21% had prior inadequate response to JAK inhibitor therapyObefazimod treatment was well tolerated with no new safety signals identified for both the 25mg and 50mg doses Abivax to present a second late-breaking abstract on October 6. Management to host a conferen

    10/5/25 11:00:00 AM ET
    $ABVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review

    Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review PARIS, France, September 12, 2025, 5:45 p.m. CEST – Abivax SA (PARIS:FR) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, announces today that following the annual review of the Euronext Paris indices on September 11, 2025, the Scientific Council of the Indices has decided to admit Abivax to the CAC Mid 60 and SBF 120 indices. This decision will take effect on Friday, September 19, 2025, after market close. The CAC

    9/12/25 11:45:00 AM ET
    $ABVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Abivax SA

    SC 13G/A - Abivax S.A. (0001956827) (Subject)

    11/14/24 9:09:55 AM ET
    $ABVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Abivax SA

    SC 13G - Abivax S.A. (0001956827) (Subject)

    4/19/24 7:09:50 PM ET
    $ABVX
    Biotechnology: Pharmaceutical Preparations
    Health Care